Unpredictable effects of rifampin as an adjunctive agent in elimination of rifampin-susceptible and -resistant Staphylococcus aureus strains grown in biofilms

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3907-3912

  Croes, Sander ^a   Beisser, Patrick S ^a   Neef, Cees ^a   Bruggeman, Cathrien A ^a   Stobberingh, Ellen E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OXACILLIN; RIFAMPICIN;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; BIOFILM; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL BIOMASS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

BIOFILMS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; OXACILLIN; RIFAMPIN; STAPHYLOCOCCUS AUREUS;

EID: 77956104982     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01811-09     Document Type: Article

References (39)

1. Baddour, L. M., W. R. Wilson, G. L. Mandell, J. E. Bennett, and R. Dolin. 2005. Infections of prosthetic valves and other cardiovascular devices, vol. 1. Churchill Livingstone Elsevier, Oxford, United Kingdom.
2. Clinical and Laboratory Standards Institute. 2009. M2-A10. Performance standards for antimicrobial disk susceptibility tests. CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2009. M100-S19. Performance standards for antimicrobial susceptibility testing. CLSI, Wayne, PA.
4. Cosgrove, S. E., and V. G. Fowler, Jr. 2007. Optimizing therapy for methicillin-resistant Staphylococcus aureus bacteremia. Semin. Respir. Crit. Care Med. 28:624-631.
5. Croes, S., R. H. Deurenberg, M. L. Boumans, P. S. Beisser, C. Neef, and E. E. Stobberingh. 2009. Staphylococcus aureus biofilm formation at the physiologic glucose concentration depends on the S. aureus lineage. BMC Microbiol. 9:229.
6. Darouiche, R. O. 2004. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-1429.
7. Deurenberg, R. H., and E. E. Stobberingh. 2008. The evolution of Staphylococcus aureus. Infect. Genet. Evol. 8:747-763.
8. Dunne, W. M., Jr., E. O. Mason, Jr., and S. L. Kaplan. 1993. Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm. Antimicrob. Agents Chemother. 37:2522-2526.
9. Enright, M. C., N. P. Day, C. E. Davies, S. J. Peacock, and B. G. Spratt. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015.
10. Forrest, G. N., and K. Tamura. 2010. Rifampin combination therapy for nonmycobacterial infections. Clin. Microbiol. Rev. 23:14-34.
11. Ghani, M., and J. S. Soothill. 1997. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa. Can. J. Microbiol. 43:999-1004.
12. Hawkins, C., J. Huang, N. Jin, G. A. Noskin, T. R. Zembower, and M. Bolon. 2007. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch. Intern. Med. 167:1861-1867.
13. Hoffman, L. R., D. A. D'Argenio, M. J. MacCoss, Z. Zhang, R. A. Jones, and S. I. Miller. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171-1175.
14. Jefferson, K. K., D. B. Pier, D. A. Goldmann, and G. B. Pier. 2004. The teicoplanin-associated locus regulator (TcaR) and the intercellular adhesin locus regulator (IcaR) are transcriptional inhibitors of the ica locus in Staphylococcus aureus. J. Bacteriol. 186:2449-2456.
15. Miro, J. M., C. Garcia-de-la-Maria, Y. Armero, D. Soy, A. Moreno, A. del Rio, M. Almela, M. Sarasa, C. A. Mestres, J. M. Gatell, M. T. Jimenez de Anta, and F. Marco. 2009. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4172-4177.
16. Murillo, O., M. E. Pachon, G. Euba, R. Verdaguer, M. Carreras, C. Cabellos, J. Cabo, F. Gudiol, and J. Ariza. 2009. Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus. J. Antimicrob. Chemother. 64:1062-1066.
17. Murillo, O., M. E. Pachon, G. Euba, R. Verdaguer, F. Tubau, C. Cabellos, J. Cabo, F. Gudiol, and J. Ariza. 2008. Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreignbody infection. Antimicrob. Agents Chemother. 52:3681-3686.
18. Nguyen, H. M., and C. J. Graber. 2010. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J. Antimicrob. Chemother. 65:24-36.
19. Nucleo, E., L. Steffanoni, G. Fugazza, R. Migliavacca, E. Giacobone, A. Navarra, L. Pagani, and P. Landini. 2009. Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii. BMC Microbiol. 9:270.
20. O'Neill, E., C. Pozzi, P. Houston, D. Smyth, H. Humphreys, D. A. Robinson, and J. P. O'Gara. 2007. Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections. J. Clin. Microbiol. 45:1379-1388.
21. Ooi, N., K. Miller, C. Randall, W. Rhys-Williams, W. Love, and I. Chopra. 2010. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J. Antimicrob. Chemother. 65:72-78.
22. Perlroth, J., M. Kuo, J. Tan, A. S. Bayer, and L. G. Miller. 2008. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch. Intern. Med. 168:805-819.
23. Rice, K. C., and K. W. Bayles. 2008. Molecular control of bacterial death and lysis. Microbiol. Mol. Biol. Rev. 72:85-109.
24. Rice, K. C., E. E. Mann, J. L. Endres, E. C. Weiss, J. E. Cassat, M. S. Smeltzer, and K. W. Bayles. 2007. The cidA murein hydrolase regulator contributes to DNA release and biofilm development in Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 104:8113-8118.
25. Riedel, D. J., E. Weekes, and G. N. Forrest. 2008. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2463-2467.
26. Rijnders, M. I., R. H. Deurenberg, M. L. Boumans, J. A. Hoogkamp-Korstanje, P. S. Beisser, and E. E. Stobberingh. 2009. Flucloxacillin, still the empirical choice for putative Staphylococcus aureus infections in intensive care units in the Netherlands. J. Antimicrob. Chemother. 64:1029-1034.
27. Ruppitsch, W., A. Indra, A. Stoger, B. Mayer, S. Stadlbauer, G. Wewalka, and F. Allerberger. 2006. Classifying spa types in complexes improves interpretation of typing results for methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 44:2442-2448. (Pubitemid 44092409)
28. Saginur, R., M. Stdenis, W. Ferris, S. D. Aaron, F. Chan, C. Lee, and K. Ramotar. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50:55-61.
29. Samuel, J. R., and F. K. Gould. 2010. Prosthetic joint infections: single versus combination therapy. J. Antimicrob. Chemother. 65:18-23.
30. Schafer, P., B. Fink, D. Sandow, A. Margull, I. Berger, and L. Frommelt. 2008. Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin. Infect. Dis. 47:1403-1409.
31. Skov, R., O. Gudlaugsson, H. Hardardottir, S. Harthug, T. Jakobsen, H. J. Kolmos, B. Olsson-Liljequist, R. Peltonen, Y. Tveten, J. Vuopio-Varkila, and C. Ahren. 2008. Proposal for common Nordic epidemiological terms and definitions for methicillin-resistant Staphylococcus aureus (MRSA). Scand. J. Infect. Dis. 40:495-502.
32. Strommenger, B., C. Kettlitz, T. Weniger, D. Harmsen, A. W. Friedrich, and W. Witte. 2006. Assignment of Staphylococcus isolates to groups by spa typing, SmaI macrorestriction analysis, and multilocus sequence typing. J. Clin. Microbiol. 44:2533-2540.
33. Svensson, E., H. Hanberger, M. Nilsson, and L. E. Nilsson. 1997. Factors affecting development of rifampicin resistance in biofilm-producing Staphylococcus epidermidis. J. Antimicrob. Chemother. 39:817-820.
34. Trampuz, A., C. K. Murphy, D. M. Rothstein, A. F. Widmer, R. Landmann, and W. Zimmerli. 2007. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob. Agents Chemother. 51:2540-2545.
35. Van der Auwera, P., J. Klastersky, J. P. Thys, F. Meunier-Carpentier, and J. C. Legrand. 1985. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob. Agents Chemother. 28:467-472.
36. Vergara-Irigaray, M., J. Valle, N. Merino, C. Latasa, B. Garcia, I. Ruiz de Los Mozos, C. Solano, A. Toledo-Arana, J. R. Penades, and I. Lasa. 2009. Relevant role of fibronectin-binding proteins in Staphylococcus aureus biofilm-associated foreign-body infections. Infect. Immun. 77:3978-3991.
37. Zavasky, D. M., and M. A. Sande. 1998. Reconsideration of rifampin: a unique drug for a unique infection. JAMA 279:1575-1577.
38. Zheng, Z., and P. S. Stewart. 2002. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother. 46:900-903.
39. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537-1541.